Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
Christophe Dupont,A. Wesley Burks,David M. Fleischer,Katharine J. Bee,Sarita Chainani,Hugh A. Sampson
DOI: https://doi.org/10.1080/1744666x.2024.2315221
2024-02-15
Expert Review of Clinical Immunology
Abstract:Introduction DBV712 250 μg (also referred to as Viaskin Peanut or peanut patch; Viaskin is a trademark of DBV Technologies) is an innovative approach to epicutaneous immunotherapy (EPIT). The patch-based technology system facilitates peanut protein (allergen) absorption into the intact non-vascularized epidermis to promote desensitization to peanut while limiting systemic allergen exposure.
immunology
What problem does this paper attempt to address?